EGFR and neoplasm: Solomon et al. have engineered a delivery system encapsulates paclitaxel with bacterial vesicles, capable of targeting the overexpressed epidermal growth factor receptor (EGFR) in solid tumor cells, thereby exerting potent anti-tumor effects in xenograft models.